![]() |
|
|
Vol. 298, Issue 1, 165-171, July 2001
Department of Pharmaceutical Sciences, University at Buffalo, The
State University of New York, Buffalo, New York
The pharmacokinetics, pharmacodynamics, and platelet binding of 7E3, an
anti-glycoprotein IIb/IIIa (GPIIb/IIIa) monoclonal antibody, were
studied in the rat in an attempt to develop a quantitative animal model of immune thrombocytopenia (ITP). 7E3, a murine
IgG1 antibody developed against human GPIIb/IIIa,
demonstrated cross-reactivity with rat platelets by flow cytometry and
via enzyme-linked immunosorbent assay. The apparent affinity
(KA) of 7E3-rat platelet binding was
1.2 ± 0.2 × 107 M
1, with 3.3 ± 0.3 × 104 binding sites per platelet. Following
intravenous 7E3 administration (0.8, 4, and 8 mg/kg), plasma
concentrations declined in a bi-exponential manner, with a terminal
half-life of 61 ± 5 h and a steady-state volume of
distribution of 62 ± 15 ml/kg. Clearance was dose-dependent, with
values ranging from 0.64 ± 0.08 ml/h/kg (8 mg/kg) to 1.01 ± 0.08 ml/h/kg (0.8 mg/kg). 7E3 induced a reproducible, severe thrombocytopenia in rats and extended bleeding in a manner consistent with human ITP. Nadir platelet counts were 79 ± 33, 25 ± 6, and 17 ± 2 × 106/ml, for 7E3 doses of 0.8, 4, and 8 mg/kg, respectively. Bleeding times after a 10-mm tail incision
ranged from 5 ± 3 min in control animals to 15 ± 0 min (the
maximum allowed time in this study) in animals receiving 8 mg/kg. Blood
volumes lost during bleeding experiments ranged from 30 ± 24 µl
(control) to 349 ± 358 µl (8 mg/kg). A reproducible,
quantitative rat model of ITP has been created; this model is expected
to facilitate the evaluation of new treatments for this disease.
This article has been cited by other articles:
![]() |
R. Deng and J. P. Balthasar Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia Blood, March 15, 2007; 109(6): 2470 - 2476. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Medina, K. Mirowsky-Garcia, J. Hutt, and B. Hjelle Ribavirin, human convalescent plasma and anti-beta3 integrin antibody inhibit infection by Sin Nombre virus in the deer mouse model J. Gen. Virol., February 1, 2007; 88(2): 493 - 505. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ni, P. Chen, C. M. Spring, E. Sayeh, J. W. Semple, A. H. Lazarus, R. O. Hynes, and J. Freedman A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy Blood, April 1, 2006; 107(7): 2976 - 2983. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-i. Hinagata, M. Kakutani, T. Fujii, T. Naruko, N. Inoue, Y. Fujita, J. L. Mehta, M. Ueda, and T. Sawamura Oxidized LDL receptor LOX-1 is involved in neointimal hyperplasia after balloon arterial injury in a rat model Cardiovasc Res, January 1, 2006; 69(1): 263 - 271. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Crow, S. Song, J. W. Semple, J. Freedman, A. H. Lazarus, R. J. Hansen, and J. P. Balthasar IVIG induces dose-dependent amelioration of ITP in rodent models Blood, February 15, 2003; 101(4): 1658 - 1659. [Full Text] [PDF] |
||||
![]() |
J.-C. Murciano, D. Harshaw, D. G. Neschis, L. Koniaris, K. Bdeir, S. Medinilla, A. B. Fisher, M. A. Golden, D. B. Cines, M. T. Nakada, et al. Platelets inhibit the lysis of pulmonary microemboli Am J Physiol Lung Cell Mol Physiol, March 1, 2002; 282(3): L529 - L539. [Abstract] [Full Text] [PDF] |
||||